AUROPHARMA - Swing Trade Analysis with AI Signals

Last Updated Time : 05 Nov 25, 7:43 am

Swing Trade Rating: 4.2

📈 AUROPHARMA shows strong short-term momentum and favorable technicals. Entry near ₹1,120–₹1,130 is optimal. If already held, consider exiting around ₹1,300–₹1,350.

📈 Positive

• 📊 Quarterly PAT surged from ₹408 Cr. to ₹559 Cr., a 37% jump.
• 📈 RSI at 63.1 and MACD at 11.2 indicate bullish momentum.
• 📉 Trading above DMA 50 (₹1,103) and DMA 200 (₹1,139) confirms upward trend.
• 💰 EPS of ₹33.7 and ROCE of 10.8% reflect solid earnings quality.
• 📈 Positive DII holding change (+0.67%) shows domestic institutional confidence.

⚠️ Limitation

• 📉 Volume below average (10.7L vs 20.8L), suggesting reduced liquidity.
• 💸 High PEG ratio of 8.00 implies overvaluation relative to growth.
• 📉 FII holding declined (-0.17%), indicating cautious foreign sentiment.
• 💰 Dividend yield of 0.35% is modest for long-term investors.

📉 Company Negative News

• ⚠️ USFDA issued five observations during inspection of Eugia Steriles, a subsidiary, leading to a 9.5% stock dip

  Upstox

  .

📈 Company Positive News

• ✅ Analysts from Religare and Anand Rathi recommend AUROPHARMA for short-term gains due to favorable technical setup

  Mint

  +1

  .

• 📈 Price target consensus around ₹1,403.50 suggests ~21% upside from current levels

  Trendlyne

  .

🏭 Industry

• 🏥 Pharma sector remains resilient amid global health concerns and regulatory tailwinds.
• 📊 Industry P/E of 33.1 aligns with AUROPHARMA’s valuation, indicating fair pricing.

✅ Conclusion

• 📈 AUROPHARMA is a strong swing trade candidate with bullish technicals and improving fundamentals.
• 📉 Optimal entry price: ₹1,120–₹1,130 (near DMA 200).
• 📈 Exit target: ₹1,300–₹1,350 (near resistance and analyst targets).
• 📌 Watch for FDA-related developments and volume confirmation before entry.

Sources

Mint

+3

I can chart AUROPHARMA’s RSI and MACD trends to help visualize its momentum—just let me know.